Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 10 de 10
1.
J BUON ; 21(1): 175-81, 2016.
Article En | MEDLINE | ID: mdl-27061546

PURPOSE: We looked for any predictive value of change in primary tumor and metastatic lymph node volumes after induction chemotherapy (IC) on oncologic outcome in head and neck squamous cell carcinoma (HNSCC). METHODS: Nineteen patients with stage IVA/B HNSCC treated between 2004 and 2010 with at least one cycle of IC (docetaxel, cisplatin and 5-fluorouracil/TPF) and concomitant chemoradiotherapy (CRT) with cisplatin were retrospectively analyzed. Volumes were calculated separately for primary tumor (Vtm), lymph node metastases (Vln) and their sum (Vsum) on computed tomography (CT) images before and after IC. The effect of volumetric changes on locoregional failure (LRF), distant metastasis (DM) and overall survival (OS) was assessed. P values <0.05 were considered as statistically significant. RESULTS: The median follow-up of surviving patients was 25 months (range: 10.7-83.3). The median number of cycles and duration of TPF was 3 (range: 1-4) and 44 days (range: 4-116), respectively. Empirical area under the curve (AUC) analyses for death, LRF and DM revealed optimal cut-off values of Vtm diminution (30.54%, AUC: 87%) and Vsum decrease (35.45%, AUC: 64.55%) only for OS (p <0.05). Among those, a reduction in Vsum more than 35.4% between pre- and post-IC was significantly correlated with better OS (100 vs 43% at 2 years, p <0.05). CONCLUSION: Volumetric shrinkage of the tumor load after IC assessed with CT seems to predict OS. The assessment of volumetric shrinkage upon IC might be used to decide whether to offer patients alternative strategies like palliative/de-intensified treatments or more aggressive combined modalities after IC.


Carcinoma, Squamous Cell/drug therapy , Head and Neck Neoplasms/drug therapy , Adult , Aged , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Head and Neck Neoplasms/mortality , Head and Neck Neoplasms/pathology , Humans , Induction Chemotherapy , Lymphatic Metastasis , Middle Aged , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck
2.
Breast Care (Basel) ; 10(4): 265-71, 2015 Aug.
Article En | MEDLINE | ID: mdl-26600763

Patients with isolated locoregional breast cancer recurrences should be treated with curative intent. Mastectomy is regarded as the standard of care for patients with ipsilateral breast tumor recurrence. In a selected group of patients, partial breast irradiation after second breast-conserving surgery is a viable alternative to mastectomy. If a second breast conservation is performed, additional irradiation should be mandatory, especially in patients who had not been irradiated previously. In case of re-irradiation, the largest experience exists for multi-catheter brachytherapy. Prospective clinical trials are needed to clearly define selection criteria, long-term local control, and toxicity. In patients with resectable locoregional breast cancer recurrences after mastectomy, multi-modal therapy comprising complete resection, radiation therapy in previously unirradiated patients, and systemic therapy results in 5-year disease-free and overall survival rates of 69% and 88%, respectively. In radiation-naive patients with unresectable, isolated locoregional recurrences, radiation therapy is mandatory. In selected patients with previous irradiations and unresectable locoregional recurrences, a second irradiation as part of an individual treatment concept can be applied. The increased risk of severe toxicity should always be weighed up against the potential clinical benefit. A combination therapy with hyperthermia can further improve the treatment results.

3.
Z Med Phys ; 25(4): 333-340, 2015 Dec.
Article En | MEDLINE | ID: mdl-26071076

OBJECTIVE: In this study, the "Progressive Resolution Optimizer PRO3" (Varian Medical Systems) is compared to the previous version "PRO2" with respect to its potential to improve dose sparing to the organs at risk (OAR) and dose coverage of the PTV for head and neck cancer patients. MATERIALS AND METHODS: For eight head and neck cancer patients, volumetric modulated arc therapy (VMAT) treatment plans were generated in this study. All cases have 2-3 phases and the total prescribed dose (PD) was 60-72 Gy in the PTV. The study is mainly focused on the phase 1 plans, which all have an identical PD of 54 Gy, and complex PTV structures with an overlap to the parotids. Optimization was performed based on planning objectives for the PTV according to ICRU83, and with minimal dose to spinal cord, and parotids outside PTV. In order to assess the quality of the optimization algorithms, an identical set of constraints was used for both, PRO2 and PRO3. The resulting treatment plans were investigated with respect to dose distribution based on the analysis of the dose volume histograms. RESULTS: For the phase 1 plans (PD = 54 Gy) the near maximum dose D2% of the spinal cord, could be minimized to 22 ± 5 Gy with PRO3, as compared to 32 ± 12 Gy with PRO2, averaged for all patients. The mean dose to the parotids was also lower in PRO3 plans compared to PRO2, but the differences were less pronounced. A PTV coverage of V95% = 97 ± 1% could be reached with PRO3, as compared to 86 ± 5% with PRO2. In clinical routine, these PRO2 plans would require modifications to obtain better PTV coverage at the cost of higher OAR doses. CONCLUSION: A comparison between PRO3 and PRO2 optimization algorithms was performed for eight head and neck cancer patients. In general, the quality of VMAT plans for head and neck patients are improved with PRO3 as compared to PRO2. The dose to OARs can be reduced significantly, especially for the spinal cord. These reductions are achieved with better PTV coverage as compared to PRO2. The improved spinal cord sparing offers new opportunities for all types of paraspinal tumors and for re-irradiation of recurrent tumors or second malignancies.


Algorithms , Head and Neck Neoplasms/radiotherapy , Organ Sparing Treatments/methods , Radiation Protection/methods , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy, Intensity-Modulated/methods , Absorption, Radiation , Humans , Organs at Risk/radiation effects , Radiotherapy Dosage , Reproducibility of Results , Scattering, Radiation , Sensitivity and Specificity
4.
Radiat Oncol ; 10: 20, 2015 Jan 17.
Article En | MEDLINE | ID: mdl-25595218

PURPOSE: To assess clinical outcomes and patterns of loco-regional failure (LRF) in relation to clinical target volumes (CTV) in patients with locally advanced hypopharyngeal and laryngeal squamous cell carcinoma (HL-SCC) treated with definitive intensity modulated radiotherapy (IMRT) and concurrent systemic therapy. METHODS: Data from HL-SCC patients treated from 2007 to 2010 were retrospectively evaluated. Primary endpoint was loco-regional control (LRC). Secondary endpoints included local (LC) and regional (RC) controls, distant metastasis free survival (DMFS), laryngectomy free survival (LFS), overall survival (OS), and acute and late toxicities. Time-to-event endpoints were estimated using Kaplan-Meier method, and univariate and multivariate analyses were performed using Cox proportional hazards models. Recurrent gross tumor volume (RTV) on post-treatment diagnostic imaging was analyzed in relation to corresponding CTV (in-volume, > 95% of RTV inside CTV; marginal, 20-95% inside CTV; out-volume, < 20% inside CTV). RESULTS: Fifty patients (stage III: 14, IVa: 33, IVb: 3) completed treatment and were included in the analysis (median follow-up of 4.2 years). Three-year LRC, DMFS and overall survival (OS) were 77%, 96% and 63%, respectively. Grade 2 and 3 acute toxicity were 38% and 62%, respectively; grade 2 and 3 late toxicity were 23% and 15%, respectively. We identified 10 patients with LRF (8 local, 1 regional, 1 local + regional). Six out of 10 RTVs were fully included in both elective and high-dose CTVs, and 4 RTVs were marginal to the high-dose CTVs. CONCLUSION: The treatment of locally advanced HL-SCC with definitive IMRT and concurrent systemic therapy provides good LRC rates with acceptable toxicity profile. Nevertheless, the analysis of LRFs in relation to CTVs showed in-volume relapses to be the major mode of recurrence indicating that novel strategies to overcome radioresistance are required.


Carcinoma, Squamous Cell/radiotherapy , Hypopharyngeal Neoplasms/radiotherapy , Laryngeal Neoplasms/radiotherapy , Lung Neoplasms/radiotherapy , Neoplasm Recurrence, Local/radiotherapy , Radiotherapy, Intensity-Modulated/methods , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/secondary , Female , Follow-Up Studies , Humans , Hypopharyngeal Neoplasms/mortality , Hypopharyngeal Neoplasms/pathology , Laryngeal Neoplasms/mortality , Laryngeal Neoplasms/pathology , Lung Neoplasms/mortality , Lung Neoplasms/secondary , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Prognosis , Radiotherapy Dosage , Retrospective Studies , Survival Rate
5.
Radiat Oncol ; 7: 175, 2012 Oct 22.
Article En | MEDLINE | ID: mdl-23088283

BACKGROUND: To determine the outcome and patterns of failure in oral cavity cancer (OCC) patients after postoperative intensity modulated radiotherapy (IMRT) with concomitant systemic therapy. METHODS: All patients with locally advanced (AJCC stage III/IV) or high-risk OCC (AJCC stage II) who underwent postoperative IMRT at our institution between December 2006 and July 2010 were retrospectively analyzed. The primary endpoint was locoregional recurrence-free survival (LRRFS). Secondary endpoints included distant metastasis-free survival (DMFS), overall survival (OS), acute and late toxicities. RESULTS: Overall 53 patients were analyzed. Twenty-three patients (43%) underwent concomitant chemotherapy with cisplatin, two patients with carboplatin (4%) and four patients were treated with the monoclonal antibody cetuximab (8%).At a median follow-up of 2.3 (range, 1.1-4.6) years the 3-year LRRFS, DMFS and OS estimates were 79%, 90%, and 73% respectively. Twelve patients experienced a locoregional recurrence. Eight patients, 5 of which had both a flap reconstruction and extracapsular extension (ECE), showed an unusual multifocal pattern of recurrence. Ten locoregional recurrences occurred marginally or outside of the high-risk target volumes. Acute toxicity grades of 2 (27%) and 3 (66%) and late toxicity grades of 2 (34%) and 3 (11%) were observed. CONCLUSION: LRRFS after postoperative IMRT is satisfying and toxicity is acceptable. The majority of locoregional recurrences occurred marginally or outside of the high-risk target volumes. Improvement of high-risk target volume definition especially in patients with flap reconstruction and ECE might transfer into better locoregional control.


Carcinoma, Squamous Cell/radiotherapy , Mouth Neoplasms/radiotherapy , Radiotherapy, Intensity-Modulated/methods , Aged , Disease-Free Survival , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Postoperative Period , Radiotherapy Dosage , Retrospective Studies , Treatment Outcome
6.
Oral Oncol ; 48(10): 1031-1037, 2012 Oct.
Article En | MEDLINE | ID: mdl-22595044

OBJECTIVES: Nasal and paranasal sinus malignancies are rare. The most common lesions are located in the nasal cavity and the maxillary sinus, although they also occur in the ethmoid, sphenoid and frontal sinuses. Treatment often combines surgery, radiotherapy and chemotherapy. Endoscopic surgical approaches are increasingly used in order to reduce the morbidity associated with standard open resection. The aim of our study was to analyse the long-term treatment results of sinonasal malignancies (SNM), with a special focus on surgical approaches. MATERIALS AND METHODS: A retrospective review of 123 patients treated in a tertiary referral centre from 1992 to 2008 was conducted, which included information on tumour stage, histology, treatment and follow-up. RESULTS: A variety of histological types were found with squamous cell carcinoma being the most frequent (n=38), followed by melanoma (n=24) and adenocarcinoma (n=21). Open surgery was performed in 55 patients, and endoscopic resection was performed in 28 patients. Nineteen patients were treated with primary radiation therapy (RTX), four underwent primary chemotherapy (CTX), and 15 had primary chemoradiation (RCTX). Two patients died prior to therapy onset. A comparison of survival rates did not show a significant difference between the treatment groups. Patients that underwent endoscopic resection had significantly fewer postoperative complications. CONCLUSION: In carefully selected patients, endoscopic surgery of SNM showed a similar outcome as open surgery, but with a significantly lower complication rate.


Adenocarcinoma/surgery , Carcinoma, Squamous Cell/surgery , Melanoma/surgery , Nose Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Endoscopy , Female , Follow-Up Studies , Humans , Male , Middle Aged , Paranasal Sinus Neoplasms/surgery , Retrospective Studies , Treatment Outcome
7.
Int J Radiat Oncol Biol Phys ; 83(4): 1205-12, 2012 Jul 15.
Article En | MEDLINE | ID: mdl-22099044

PURPOSE: To analyze the outcome after low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy for lip cancer. METHODS AND MATERIALS: One hundred and three patients with newly diagnosed squamous cell carcinoma of the lip were treated between March 1985 and June 2009 either by HDR (n = 33) or LDR brachytherapy (n = 70). Sixty-eight patients received brachytherapy alone, and 35 received tumor excision followed by brachytherapy because of positive resection margins. Acute and late toxicity was assessed according to the Common Terminology Criteria for Adverse Events 3.0. RESULTS: Median follow-up was 3.1 years (range, 0.3-23 years). Clinical and pathological variables did not differ significantly between groups. At 5 years, local recurrence-free survival, regional recurrence-free survival, and overall survival rates were 93%, 90%, and 77%. There was no significant difference for these endpoints when HDR was compared with LDR brachytherapy. Forty-two of 103 patients (41%) experienced acute Grade 2 and 57 of 103 patients (55%) experienced acute Grade 3 toxicity. Late Grade 1 toxicity was experienced by 34 of 103 patients (33%), and 5 of 103 patients (5%) experienced late Grade 2 toxicity; no Grade 3 late toxicity was observed. Acute and late toxicity rates were not significantly different between HDR and LDR brachytherapy. CONCLUSIONS: As treatment for lip cancer, HDR and LDR brachytherapy have comparable locoregional control and acute and late toxicity rates. HDR brachytherapy for lip cancer seems to be an effective treatment with acceptable toxicity.


Brachytherapy/methods , Carcinoma, Squamous Cell/radiotherapy , Lip Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Brachytherapy/adverse effects , Brachytherapy/mortality , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Disease-Free Survival , Female , Humans , Lip Neoplasms/mortality , Lip Neoplasms/pathology , Male , Middle Aged , Neoplasm Recurrence, Local/radiotherapy , Radiotherapy Dosage , Retrospective Studies , Switzerland , Tumor Burden
8.
Case Rep Med ; 2010: 321835, 2010.
Article En | MEDLINE | ID: mdl-20368796

We present a case of a Rendu-Osler-Weber disease patient with recurrent life threatening epistaxis demanding multiple blood transfusions despite of repetitive endoscopic laser and electrocoagulations, endovascular embolisation, septodermoplasty, and long-term intranasal dressings. As alternative treatment modalities repeatedly failed and the patient became almost permanently dependent on nasal dressing, we performed a highly conformal intensity-modulated radiotherapy of the nasal cavity; a total dose of 50 Gy in 2 Gy single fractions was applied. The therapy was very well tolerated, no acute toxicities occurred. Two weeks after the last radiation dose had been applied, the nasal dressing could be removed without problems. Endoscopical control revealed an almost avascular white mucosa without any trace of bleeding spots; previously existing hemangiomas and crusts had disappeared. After a 1-year-follow up, the patient had no significant recurrent epistaxis.

9.
Int J Radiat Oncol Biol Phys ; 76(4): 1127-32, 2010 Mar 15.
Article En | MEDLINE | ID: mdl-19647955

PURPOSE: We performed a histopathologic analysis to assess the extent of the extracapsular extension (ECE) beyond the capsule of metastatic lymph nodes (LN) in head and neck cancer to determine appropriate clinical target volume (CTV) expansions. METHODS AND MATERIALS: All tumor-positive LN of 98 patients who underwent a neck dissection with evidence of ECE in at least one LN were analyzed by a single pathologist. The largest diameters of all LN, and in the case of ECE, the maximal linear distance, from the capsule to the farthest extent of tumor or tumoral reaction were recorded. RESULTS: A total of 231 LN with ECE and 200 tumor-positive LN without ECE were analyzed. The incidence of ECE was associated with larger LN size (p < 0.001). Of all tumor-positive LN with a diameter of < 10 mm or < 5 mm, 105/220 (48%) nodes or 17/59 (29%) nodes, respectively, showed evidence of ECE. The mean and median extent values of ECE were 2 and 1 mm (range, 1-10 mm) and the ECE was < or = 5 mm in 97% and < or = 3 mm in 91% of the LN, respectively. Overall, the extent of ECE was significantly correlated with larger LN size (Spearman's correlation coefficient = 0.21; p = 0.001). CONCLUSIONS: The incidence of ECE is associated with larger LN size. However, ECE is found in a substantial number of LN with a diameter of < 10 mm. The use of 10-mm CTV margins around the gross tumor volume seems appropriate to account for ECE in radiotherapy planning of head and neck cancer.


Carcinoma, Squamous Cell/secondary , Head and Neck Neoplasms/pathology , Lymph Nodes/pathology , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Female , Head and Neck Neoplasms/radiotherapy , Head and Neck Neoplasms/surgery , Humans , Hypopharyngeal Neoplasms/pathology , Laryngeal Neoplasms/pathology , Lymphatic Metastasis/pathology , Male , Middle Aged , Mouth Neoplasms/pathology , Neck Dissection , Oropharyngeal Neoplasms/pathology , Statistics, Nonparametric , Tumor Burden
10.
J Pediatr Orthop B ; 14(4): 262-5, 2005 Jul.
Article En | MEDLINE | ID: mdl-15931029

Femoral varus osteotomy is an established therapy for Legg-Calvé-Perthes disease. The amount of surgical varus angulation is usually measured as the difference between the preoperative and the postoperative projected femur neck-shaft angle. We developed a more accurate measurement technique that considers changes of leg position and assessed the surgical varus angulation on two postoperative radiographs of each of 65 uniplanar femoral varus osteotomies. The mean difference between both surgical varus angulation measurements was 2.0 degrees +/- 1.4 degrees (range 0.0-5.0 degrees), the Pearson's correlation result was r = 0.96. The mean surgical varus angulation was 18.7 degrees +/- 7.3 degrees (range -2.5 to 43.5 degrees). Comparison with the preoperatively planned angulation showed a mean difference of 6.6 +/- 5.2 degrees (range 0.25-22.5 degrees).


Femur Head/diagnostic imaging , Femur Head/surgery , Legg-Calve-Perthes Disease/diagnostic imaging , Legg-Calve-Perthes Disease/surgery , Osteotomy , Child , Child, Preschool , Female , Humans , Male , Postoperative Period , Preoperative Care , Radiography , Retrospective Studies
...